Source: Rounding The Earth Author: Mathew Crawford Fifty years ago today, the New York Times began publication of the Pentagon Papers, informing the public about how a government-engineered
“For science to work, you have to have an open exchange of ideas,” Bhattacharya said of the censorship. “If you’re going to make an argument that something is misinformation, you should provide an actual argument. You can’t just take it down and say, ‘Oh, it’s misinformation’ without actually giving a reason.
“We found that when the cumulative doses of two drugs, HCQ and AZM, were above a certain level, patients had a survival rate 2.9 times the other patients,” the authors of the study noted.
There are so many ways to attack this virus, so we’ll move forward with an argument that SARS-CoV-2 is far easier to handle than its public image suggests.
In a letter dated the 23rd of April, 2021, four Guest Editors publicly resigned from the journal Frontiers in Pharmacology. Professor Maria Cristina Albertini, Professor Piero Sestili, Dr. Robert Malone, and Dr. Howard Haimes stepped down in protest over executive decisions not to publish two papers showing positive results of various agents in protecting against or treating COVID-19.
Bret, Pierre, Heather, and a large number of internet pundits make a great case that suppression of ivermectin is a large, gross, and inhumane crime. However, this is not the “crime of the century”. The crime of the century is far larger, or rather more systemic.
Over 10,000 patients,a fatality rate more than 97% LOWER than France’s – an exceptional case for early treatment with a drug regimen including HCQ & AZM.
Most Covid studies have not considered days of therapy, cumulative dose, or weight-adjusted dosing. We found that when the cumulative doses of two drugs, HCQ and AZM, were above a certain level, patients had a survival rate 2.9 times the other patients. By using causal analysis and considering of weight-adjusted cumulative dose, we prove the combined therapy, >3 g HCQ and > 1g AZM greatly increases survival in Covid patients on IMV and that HCQ cumulative dose > 80 mg/kg works substantially better. These data do not yet apply to hospitalized patients not on IMV. Since those with higher doses of HCQ had higher doses of AZM, we cannot solely attribute the causal effect to HCQ/AZM combination therapy. However, it is likely AZM does contribute significantly to this increase in survival rate. Since higher dose HCQ/AZM therapy improves survival by nearly 200% in this population, the safety data are moot. However, given the data presented here, the studies reporting HCQ’s effect of QTc intervals need to be re-evaluated.
“The significant decline is a tremendous achievement in the fight against COVID-19 and further bolsters our appeal to undertake mass distribution of ivermectin to our people.”
The kits distributed included ivermectin, aspirin and paracetamol. Between the end of November 2020 and the end of January 2021, more than 200,000 people tested positive for COVID, and of these, nearly 80,000 used the ivermectin kits. Results showed up to 76% reduction in hospitalization in the group that was taking ivermectin.
Zero patients in the ivermectin group that became hospitalized (as compared to 3 in the control group), the results were overall impressive.
McCullough walks through a thorough (if basic) coverage of many drugs and nutraceuticals that have been effectively used around the world—the best single such coverage seen packed into one video.
Major benefits of ivermectin (IVM) treatment for COVID-19 have been known since the results of 20 such randomized controlled trials (RCTs) were reported
TrialSite hosted the first international Ivermectin for Covid Summit webinar on Sunday, May 23rd 2021. The event was widely attended with medical experts presenting from around the world to a global audience of interested parties in the thousands.
TrialSite hosted the first international Ivermectin for Covid Summit webinar on Sunday, May 23rd 2021. The event was widely attended with medical experts presenting from around the world to a global audience of interested parties in the thousands.
Leading the national trial is Dr. Carolyn Bramante, a U internal medicine specialist. Emphasizing the importance of this trial, she says, “Not everybody has access to the vaccine, whereas these medications are existing generics, already FDA-approved, that are available in most pharmacies around the world.” Dr. Bramante continued, “If we find evidence of benefit, [the drugs] could be used immediately anywhere.”
Dr Richard Urso uncovers a hugely significant detail in a chloroquine study. Chloroquine will protect a normal cell & let the virus attack a cancer cell.
Doctors have found safe, effective and inexpensive treatments that work well in preventing and treating patients with COVID-19 like Ivermectin that’s been used safely for more than 30 years.
But the government has not supported the use of this effective drug. In fact, there are other therapies like hydroxychloroquine, vitamins D and C and zinc that physicians have found to be safe and effective in preventing and treating COVID.
Dr. Pierre Kory explain both the case that ivermectin (IVM) effectively prevents or treats COVID-19, and also how and why that information is withheld by public health officials.
But while political psychology did its thing, making HCQ a no go zone for many physicians, Tyson and his staff simply treated patients according to whatever seemed to work, using HCQ as a primary option. And work it did.
We are very honored to present this interview of Dr Vladimir Zelenko, the father of outpatient treatment for COVID-19 in North America. Dr Zelenko shares his own experience with COVID-19 as a patient, as he is recovering from a severe form of the disease.
He also talks about his cancer and how he was able to go through this dramatic episode of his life. Then, he presents his perspectives about outpatient treatment as practiced today and the evolution of the pandemic, among other topics.
Significant QT prolongation was not observed during the follow‐up period compared with the baseline values in the present study. No ventricular arrhythmias, second and third‐degree heart blocks, or severe pauses were recorded during the treatment period.
The International Ivermectin for Covid Conference: Dr. Wasif Khan presents his published ivermectin trial and his experience with using ivermectin in Bangladesh.
Medical experts from around the world joined together to present the very latest real world research on repurposing this safe drug that has the ability to transform global efforts to fight the pandemic. Prof. Pierre Kory discusses current protocols for covid-19 prevention and treatment.
The International Ivermectin for Covid Conference: Professor Eli Schwartz shares data and conclusions from his Israeli randomised controlled trial of ivermectin in mild to moderate covid-19.
Medical experts from around the world joined together to present the very latest real world research on repurposing ivermectin that has the ability to transform global efforts to fight the pandemic. Mr. Andrew Bryant provides an overview of ongoing trials and what they may add to the evidence base.
The International Ivermectin for Covid Conference:
Dr. Tess Lawrie presents the latest systematic review evidence from RCTs and a selection of resource, equity, acceptability and feasibility considerations related to ivermectin use for COVID-19
HCQ is effective for COVID-19. The probability that an ineffective treatment generated results as positive as the 235 studies to date is estimated to be 1 in 6 quadrillion (p = 0.00000000000000018).
Early treatment is most successful, with 100% of 29 studies reporting a positive effect (13 statistically significant in isolation) and an estimated reduction of 65% in the effect measured (death, hospitalization, etc.) using a random effects meta-analysis, RR 0.35 [0.25-0.50].
92% of Randomized Controlled Trials (RCTs) for early, PrEP, or PEP treatment report positive effects, the probability of this happening for an ineffective treatment is 0.0017.
With a surge of SARS-CoV-2 infections and a vaccination drive totaling 1.3 million, the nation’s leadership faces an uphill battle when factoring in their total population of 108 million. Hence the growing interest in ivermectin and the request of hospitals for access to the drug for compassionate use.
NIH will provide an initial investment of $155 million in funding for the trial. TrialSite picked up inside rumblings that ivermectin will be one of the economical drugs under investigation. While this study is late in the pandemic, nonetheless TrialSite celebrates Collins and team’s movement in this most important of areas. We don’t currently have approved medication to be self-administered by people suffering mild disease at home & reduce the chance of needing hospitalization.
It is high time to open our eyes, to hold our governments to account, and to fundamentally reform a system that has been misled by the interests of the all-powerful pharmaceutical industry. ”
In an interview with Alan Jones, Craig Kelly MP discusses the vaccine rollout mishaps and yet again, rightfully points out the myriad of medical specialists around the world who support the use of ivermectin for the prophylaxis and treatment of their Covid-19 patients with the backup of extensive positive data.
Source: The New American Author: Annalisa Pesek Calls are increasing for investigations into Dr. Anthony Fauci’s intentional suppression of inexpensive and easily accessible, life-saving treatments for COVID-19.
It would be a historically amazing feat of maneuvering bureaucracy, worthy of its own epic book, movie, or perhaps a campfire song, to have wrangled that much data out of those hospitals with highly variable regulations and procedures, nearly all of which are in the U.S. healthcare system.
The severe weaknesses of this study make it uninformative about whether ivermectin is beneficial in early COVID-19 treatment. Yet, the authors misleadingly conclude that their findings “do not support the use of ivermectin for treatment of mild COVID-19”, as if they had enough quality data to make that case, which they do not.
FLCCC Weekly Update: “Big Science vs Little Science”—April 14, 2021 Drs. Jose Morgenstern and Jose Redondo of the Dominican Republic share their new ivermectin study and tell the story of how they discovered the efficacy of ivermectin in April, 2020.
It was in these very moments in late May when public health officials lost all credibility—a credibility that cannot be restored without major changes taking place. Despite most evidence pointing to a likelihood of HCQ efficacy, they made their call on the back of data supposedly tucked away in a database that nobody had verified, declared it definitive, then swiftly pushed for policy changes around the world.
Hydroxychloroquine also can act as an oral hypoglycemic agent, as patients with diabetes taking hydroxychloroquine for rheumatologic diseases had a significant reduction in hemoglobin A1c when compared to methotrexate,40 and thus can serve to reduce hyperglycemia, a possible COVID‐19 risk factor for disease severity.
The authors emphasize the historically significant & relevant role of empiric treatment in an attempt to reduce death. Doing nothing is not good medicine.
